Skip to main content
Premium Trial:

Request an Annual Quote

InterGenetics Readies New HQ, Lab for OncoVue Testing

NEW YORK, Sept. 7 (GenomeWeb News) - InterGenetics has completed construction on a new 11,000-square-foot headquarters and laboratory in Oklahoma City in preparation for what it expects to be high demand for its genetic-based OncoVue breast-cancer risk predictive test. The company anticipates will be available next month, the firm said today.

According to InterGenetics, the firm expects it will recieve federal certification to perform the testing under CLIA standards, and InterGenetics is projecting that 15,000 of the tests will be processed within the first 12 months of the lab's operation.

In addition, InterGenetics CEO and President Craig Shimasaki said the company had secured $8 million worth of financing this summer that will aid in launching the OncoVue service, which InterGenetics claims "can determine the lifetime and age-specific risk of developing breast cancer for all women..

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.